Background: Coagulase negative staphylococci (CoNS) are an important group of multi-drug resistant nosocomial pathogens. Clindamycin resistance in staphylococci can be either constitutive or inducible. Clindamycin has been used successfully to treat pneumonia, soft-tissue and musculoskeletal infections due to methicillin-resistant CoNS (MRCoNS) in adults and children, but this matter is complicated by the possibility of inducible macrolide-lincosamide streptogramin B resistance (MLSBi). Aims: The present study was aimed to determine the incidence of inducible clindamycin resistance in CoNS isolates in our hospital using D-test, relationship between MRCoNS and MLSBi isolates, association of MLSBi isolates with community or nosocomial setting and treatment options for these isolates. Materials and Methods: A total of 250 consecutive, non-duplicate strains of CoNS were isolated from various clinical specimens, both from indoor and outdoor patients. After determining methicillin resistance, D-test was performed on all erythromycin-resistant and clindamycin-sensitive isolates to detect inducible clindamycin resistance. Results: Among 250 CoNS isolates, 89 (35.6%) were found to be MRCoNS and 20% had MLSBi phenotype. MRCoNS showed higher inducible as well as constitutive resistance (p<0.0001) to clindamycin as compared to methicillin-sensitive CoNS (MSCoNS). All isolates having MLSBi phenotype were sensitive to vancomycin and linezolid. Conclusions: Clindamycin is a useful drug in the treatment of staphylococcal infections. Hence, routine testing of staphylococcal isolates for inducible clindamycin resistance is strongly recommended.